{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T15:41:18Z","timestamp":1657467678536},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,4,17]],"date-time":"2003-04-17T00:00:00Z","timestamp":1050537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1007\/s00108-003-0927-3","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T21:47:38Z","timestamp":1476740858000},"page":"701-710","source":"Crossref","is-referenced-by-count":0,"title":["Nebenwirkungen der antiretroviralen Therapie"],"prefix":"10.1007","volume":"44","author":[{"given":"U.","family":"Seybold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Draenert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.-D.","family":"Goebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,4,17]]},"reference":[{"key":"0927_CR1","doi-asserted-by":"crossref","unstructured":"Palella FJ, Delaney KM, Moorman AC et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study. N Engl J Med 26: 853\u2013860","DOI":"10.1056\/NEJM199803263381301"},{"key":"0927_CR2","doi-asserted-by":"crossref","unstructured":"Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51\u201358","DOI":"10.1097\/00002030-199807000-00003"},{"key":"0927_CR3","doi-asserted-by":"crossref","unstructured":"Ault A (1997) FDA warns of potential protease-inhibitor link to hyperglycaemia. Lancet 349: 1819","DOI":"10.1016\/S0140-6736(05)61703-5"},{"key":"0927_CR4","doi-asserted-by":"crossref","unstructured":"Constans J, Pellegrin JL, Peuchant E et al. (1994) Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 24: 416\u2013420","DOI":"10.1111\/j.1365-2362.1994.tb02185.x"},{"key":"0927_CR5","doi-asserted-by":"crossref","unstructured":"Segerer S, Bogner JR, Walli R, Loch O, Goebel FD (1999) Hyperlipidemia under treatment with proteinase inhibitors. Infection 27: 77\u201381","DOI":"10.1007\/BF02560501"},{"key":"0927_CR6","doi-asserted-by":"crossref","unstructured":"Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO (2003) Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 17: 189\u2013194","DOI":"10.1097\/00002030-200301240-00008"},{"key":"0927_CR7","doi-asserted-by":"crossref","unstructured":"Schmitz M, Michl GM, Walli R et al. (2001) Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr 26: 225\u2013235","DOI":"10.1097\/00126334-200103010-00004"},{"key":"0927_CR8","unstructured":"Pozniak AL, Staszewski S, Gallant J et al. (2002) Comparison of the efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART) after 48 weeks of treatment. 6th International Congress on Drug Therapy in HIV Infection, November 17\u201321, Glasgow, UK"},{"key":"0927_CR9","doi-asserted-by":"crossref","unstructured":"Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP (1991) Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 40: 651\u2013656","DOI":"10.1016\/0026-0495(91)90059-6"},{"key":"0927_CR10","doi-asserted-by":"crossref","unstructured":"Walli R, Herfort O, Michl GM et al. (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12: F167\u2013173","DOI":"10.1097\/00002030-199815000-00001"},{"key":"0927_CR11","doi-asserted-by":"crossref","unstructured":"Brinkman K (2000) Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 31: 167\u2013169","DOI":"10.1086\/313921"},{"key":"0927_CR12","unstructured":"Flint OP, Mulvey R, Wang S, et al. (2001) Nucleoside reverse transcriptase inhibitors: inhibition of mitochondrial DNA replication, but no effect on adiposity in an obese mouse model. Antivir Ther 6 (Suppl 4): 17"},{"key":"0927_CR13","unstructured":"Caron M, Auclair M, Kornprobst M, Capeau J (2002) Stavudine and didanosine partly reversed the adverse effects of indinavir on cell differentiation and response to insulin but enhanced apoptosis of cultured adipocytes. Antivir Ther 7: L6"},{"key":"0927_CR14","doi-asserted-by":"crossref","unstructured":"Domingo P, Matias-Guiu X, Pujol RM, Francia E, Lagarda E, Sambeat MA, Vazquez G (1999) Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 13: 2261\u20132267","DOI":"10.1097\/00002030-199911120-00008"},{"key":"0927_CR15","doi-asserted-by":"crossref","unstructured":"Murata H, Hruz PW, Mueckler M (2000) The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275: 20251\u201320254","DOI":"10.1074\/jbc.C000228200"},{"key":"0927_CR16","doi-asserted-by":"crossref","unstructured":"Murata H, Hruz PW, Mueckler M (2002) Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy. Curr Drug Targets Infect Disord 2: 1\u20138","DOI":"10.2174\/1568005024605882"},{"key":"0927_CR17","doi-asserted-by":"crossref","unstructured":"Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C (2001) Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15: F11\u201318","DOI":"10.1097\/00002030-200105040-00001"},{"key":"0927_CR18","doi-asserted-by":"crossref","unstructured":"Behrens GM, Boerner AR, Weber K, van den Hoff J, Ockenga J, Brabant G, Schmidt RE (2002) Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 110: 1319\u20131327","DOI":"10.1172\/JCI200215626"},{"key":"0927_CR19","doi-asserted-by":"crossref","unstructured":"Bastard JP, Caron M, Vidal H et al. (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026\u20131031","DOI":"10.1016\/S0140-6736(02)08094-7"},{"key":"0927_CR20","doi-asserted-by":"crossref","unstructured":"Dresner A, Laurent D, Marcucci M et al. (1999) Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103: 253\u2013259","DOI":"10.1172\/JCI5001"},{"key":"0927_CR21","unstructured":"Grinspoon SK (2003) The pathophysiology of HIV-1 related insulin resistance and dyslipemia. 10th Conference on Retroviruses and Opportunistic Infections, February 10\u201314, Boston, MA, USA"},{"key":"0927_CR22","unstructured":"Capeau J (2003) Progress in understanding the pathogenesis of HIV-1 related lipodystrophy. 10th Conference on Retroviruses and Opportunistic Infections, February 10\u201314, Boston, MA, USA"},{"key":"0927_CR23","doi-asserted-by":"crossref","unstructured":"Hruz PW, Murata H, Qiu H, Mueckler M (2002) Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 51: 937\u2013942","DOI":"10.2337\/diabetes.51.4.937"},{"key":"0927_CR24","doi-asserted-by":"crossref","unstructured":"Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50: 1378\u20131388","DOI":"10.2337\/diabetes.50.6.1378"},{"key":"0927_CR25","doi-asserted-by":"crossref","unstructured":"Roche R, Poizot-Martin I, Martin-El Yazidi C, Compe E, Gastaut JA, Torresani J, Planells R (2002) Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 16: 13\u201320","DOI":"10.1097\/00002030-200201040-00003"},{"key":"0927_CR26","doi-asserted-by":"crossref","unstructured":"Vigouroux C, Auclair M, Dubosclard E, Pouchelet M, Capeau J, Courvalin JC, Buendia B (2001) Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q\/W mutations in the lamin A\/C gene. J Cell Sci 114: 4459\u20134468","DOI":"10.1242\/jcs.114.24.4459"},{"key":"0927_CR27","unstructured":"Jones SP, Janneh O, Maher B, Khoo S, Back DJ, Pirmohamed M (2002) Altered TNF-\u03b1 and IL-6 levels and the antiadipogenic effects on cultured adipocytes: possible mechanism for their role in lipodystrophy in HIV-infected patients. Antivir Ther 7: L2"},{"key":"0927_CR28","doi-asserted-by":"crossref","unstructured":"Sewter C, Berger D, Considine RV et al. (2002) Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha. Diabetes 51: 1035\u20131041","DOI":"10.2337\/diabetes.51.4.1035"},{"key":"0927_CR29","doi-asserted-by":"crossref","unstructured":"Bastard JP, Caron M, Vidal H et al. (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026\u20131031","DOI":"10.1016\/S0140-6736(02)08094-7"},{"key":"0927_CR30","doi-asserted-by":"crossref","unstructured":"van der Valk M, Bisschop PH, Romijn JA et al. (2001) Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15: 2093\u20132100","DOI":"10.1097\/00002030-200111090-00004"},{"key":"0927_CR31","doi-asserted-by":"crossref","unstructured":"Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S (2002) Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 51: 1143\u20131147","DOI":"10.1053\/meta.2002.34704"},{"key":"0927_CR32","doi-asserted-by":"crossref","unstructured":"Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS (2003) Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 88: 627\u2013636","DOI":"10.1210\/jc.2002-020795"},{"key":"0927_CR33","unstructured":"Dinges WL, Chen D, Shimomura I, Matsuzawa Y, Peterson DM, Garg A (2003) Adipocytokine levels in the lipodystrophy syndrome of HIV-infected patients. 10th Conference on Retroviruses and Opportunistic Infections, February 10\u201314, Boston, MA, USA"},{"key":"0927_CR34","unstructured":"Johnson JA, Albu JB, He Q, Engelson ES, Kotler DP (2001) Elevated in vitro tumor necrosis factor \u03b1 release from abdominal subcutaneous adipose tissue (sat) in HIV-Infected subjects with lipodystrophy. Antivir Ther 6 (Suppl 4): 16\u201317"},{"key":"0927_CR35","doi-asserted-by":"crossref","unstructured":"Christeff N, Melchior JC, de Truchis P, Perronne C, Gougeon ML (2002) Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest 32: 43\u201350","DOI":"10.1046\/j.0014-2972.2001.00940.x"},{"key":"0927_CR36","doi-asserted-by":"crossref","unstructured":"Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M (2002) TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16: 2013\u20132018.","DOI":"10.1097\/00002030-200210180-00005"},{"key":"0927_CR37","doi-asserted-by":"crossref","unstructured":"Nolan D, Moore C, Castley A, Sayer D, Mamotte C, John M, James I, Mallal S (2003) Tumour necrosis factor-alpha gene 238G\/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17: 121\u2013123","DOI":"10.1097\/00002030-200301030-00017"},{"key":"0927_CR38","doi-asserted-by":"crossref","unstructured":"Tomlinson JW, Moore J, Cooper MS et al. (2001) Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142: 1982\u20131989","DOI":"10.1210\/endo.142.5.8168"},{"key":"0927_CR39","doi-asserted-by":"crossref","unstructured":"Renard E, Fabre J, Paris F, Reynes J, Bringer J (1999) Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf) 51: 223\u2013230","DOI":"10.1046\/j.1365-2265.1999.00777.x"},{"key":"0927_CR40","doi-asserted-by":"crossref","unstructured":"Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, Grinspoon S (2001) Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 86: 504\u2013310","DOI":"10.1210\/jc.86.2.504"},{"key":"0927_CR41","doi-asserted-by":"crossref","unstructured":"Torres RA, Unger KW, Cadman JA, Kassous JY (1999) Recombinant human growth hormone improves truncal adiposity and \"buffalo humps\" in HIV-positive patients on HAART. AIDS 13: 2479\u20132481","DOI":"10.1097\/00002030-199912030-00023"},{"key":"0927_CR42","doi-asserted-by":"crossref","unstructured":"Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M (1999) Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13: 2099\u20132103","DOI":"10.1097\/00002030-199910220-00013"},{"key":"0927_CR43","doi-asserted-by":"crossref","unstructured":"Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, Kotler DP (2002) Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 30: 379\u2013391","DOI":"10.1097\/00042560-200208010-00002"},{"key":"0927_CR44","doi-asserted-by":"crossref","unstructured":"Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351: 1958","DOI":"10.1016\/S0140-6736(98)26026-0"},{"key":"0927_CR45","doi-asserted-by":"crossref","unstructured":"Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, Montanera JS (2001) Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV\/AIDS treatment. AIDS 15: 231\u2013239","DOI":"10.1097\/00002030-200101260-00013"},{"key":"0927_CR46","doi-asserted-by":"crossref","unstructured":"Friis-M\u00f8ller N, Weber R, D'Arminio Monforte A et al. (2003) Exposure to HAART Is associated with an increased risk of myocardial infarction: The D:A:D Study. 10th Conference on Retroviruses and Opportunistic Infections, February 10\u201314, Boston, MA, USA","DOI":"10.2165\/00128413-200313780-00026"},{"key":"0927_CR47","doi-asserted-by":"crossref","unstructured":"Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348: 702\u2013710","DOI":"10.1056\/NEJMoa022048"},{"key":"0927_CR48","doi-asserted-by":"crossref","unstructured":"Clumeck N, Goebel FD, Rozenbaum W et al. (2001) Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15: 1517\u20131526","DOI":"10.1097\/00002030-200108170-00009"},{"key":"0927_CR49","unstructured":"Walli RK, Michl GM, Bogner JR, Goebel FD (2001) Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 6: 413\u2013421"},{"key":"0927_CR50","doi-asserted-by":"crossref","unstructured":"Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13: 805\u2013810","DOI":"10.1097\/00002030-199905070-00009"},{"key":"0927_CR51","doi-asserted-by":"crossref","unstructured":"Martinez E, Mocroft A, Garcia-Viejo MA et al. (2001) Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357: 592\u2013598","DOI":"10.1016\/S0140-6736(00)04056-3"},{"key":"0927_CR52","doi-asserted-by":"crossref","unstructured":"Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S (2000) Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 284: 472\u2013477","DOI":"10.1001\/jama.284.4.472"},{"key":"0927_CR53","doi-asserted-by":"crossref","unstructured":"Walli R, Michl GM, Muhlbayer D, Brinkmann L, Goebel FD (2000) Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 199: 253\u2013262","DOI":"10.1007\/s004330050123"},{"key":"0927_CR54","unstructured":"Sutinen J, Hakkinen AM, Westerbacka J et al. (2002) Rosiglitazone in the treatment of HAART associated lipodystrophy (HAL): a randomized, double-blind, placebo-controlled study. 9th Conference on Retroviruses and Opportunistic Infections, February 24\u201328, Seattle, WA, USA"},{"key":"0927_CR55","doi-asserted-by":"crossref","unstructured":"Gelato MC, Mynarcik DC, Quick JL et al. (2002) Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 31: 163\u2013170","DOI":"10.1097\/00126334-200210010-00006"},{"key":"0927_CR56","doi-asserted-by":"crossref","unstructured":"Arioglu E, Duncan-Morin J, Sebring N et al. (2000) Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133: 263\u2013274","DOI":"10.7326\/0003-4819-133-4-200008150-00009"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-003-0927-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-003-0927-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-003-0927-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-003-0927-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T15:21:50Z","timestamp":1657466510000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-003-0927-3"}},"subtitle":["Aspekte der Pathogenese"],"short-title":[],"issued":{"date-parts":[[2003,4,17]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["0927"],"URL":"https:\/\/doi.org\/10.1007\/s00108-003-0927-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,17]]}}}